Clinical Trial Recruitment Lab
Clinical Trial Recruitment Lab
Program Leadership

Director, Alzheimer’s Therapeutic Research Institute

Nonresident Scholar, USC Schaeffer Institute

Founding Director, USC Schaeffer Institute

Co-Director, Aging and Cognition Program, USC Schaeffer Center

Research Program Lead, USC Schaeffer Center

Director, Alzheimer’s Trial Recruitment Innovation Lab
Top Stories View All
News
USC Initiative Awards Funding to Test AI-Driven Strategies to Accelerate Alzheimer’s Clinical Trials
Featured Experts: Dana Goldman, Paul Aisen
In The News View All
No news items.
Clinical Trial Knowledge Hub
Stronger, more efficient clinical trial recruitment can help accelerate the search for new Alzheimer’s treatments. The Knowledge Hub brings together evidence from our innovative pilots, best practices from the field and insights from leading researchers.
Learn MoreFeatured White Paper
Key Barriers for Clinical Trials for Alzheimer’s Disease
Alzheimer’s disease (AD) clinical trials are more complicated, costly, and slower than trials for other diseases. Addressing barriers would accelerate the approval of innovative therapies.
Experts: Dana Goldman, Niranjan Bose
Improving the Clinical Trial Ecosystem
CTRL convened leading experts to examine how new technologies are transforming clinical trial recruitment, strategies for overcoming persistent barriers and the value of enabling earlier intervention.
Watch Here
Ongoing Studies
The Alzheimer’s Trial Recruitment Innovation Lab (ATRIL) seeks to diversify participant recruitment and accelerate the process of enrolling a representative population in preclinical and prodromal Alzheimer’s clinical trials through evidence-based science, community engagement and training.
Alzheimer’s Trial Recruitment Innovation LabMore Clinical Trial Research View All
News
USC Initiative Awards Funding to Test AI-Driven Strategies to Accelerate Alzheimer’s Clinical Trials
Featured Experts: Dana Goldman, Paul Aisen
In The News View All
MedPage Today
Kanter discusses changes in staffing and decision-making at the FDA
Featured Experts: Genevieve P. Kanter
Axios
Schiller discusses opportunities to strengthen U.S. competitiveness in early-phase clinical research
Featured Experts: Lowell Schiller
STAT
FDA staff cuts may undermine agency promises on “radical transparency” and fewer conflicts of interest, Kanter explains
Featured Experts: Genevieve P. Kanter
Barron's
Grogan quoted on the competitive threat the U.S. faces from Chinese biotech
Featured Experts: Joseph Grogan
ABC News
Padula says pharmaceutical tariffs could hit R&D budgets
Featured Experts: William Padula